Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.

To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A, Johnson P, Berquin IM, Royer HD, Eaves CJ, Dunn SE.

Cancer Res. 2010 Apr 1;70(7):2840-51. doi: 10.1158/0008-5472.CAN-09-3155. Epub 2010 Mar 23.

2.

The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.

Dhillon J, Astanehe A, Lee C, Fotovati A, Hu K, Dunn SE.

Oncogene. 2010 Nov 25;29(47):6294-300. doi: 10.1038/onc.2010.365. Epub 2010 Aug 30.

PMID:
20802512
3.

Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.

Stratford AL, Reipas K, Hu K, Fotovati A, Brough R, Frankum J, Takhar M, Watson P, Ashworth A, Lord CJ, Lasham A, Print CG, Dunn SE.

Stem Cells. 2012 Jul;30(7):1338-48. doi: 10.1002/stem.1128.

4.

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).

Reipas KM, Law JH, Couto N, Islam S, Li Y, Li H, Cherkasov A, Jung K, Cheema AS, Jones SJ, Hassell JA, Dunn SE.

Oncotarget. 2013 Feb;4(2):329-45.

5.

YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.

Davies AH, Reipas KM, Pambid MR, Berns R, Stratford AL, Fotovati A, Firmino N, Astanehe A, Hu K, Maxwell C, Mills GB, Dunn SE.

Stem Cells. 2014 Jun;32(6):1437-50. doi: 10.1002/stem.1707.

6.

P-cadherin is coexpressed with CD44 and CD49f and mediates stem cell properties in basal-like breast cancer.

Vieira AF, Ricardo S, Ablett MP, Dionísio MR, Mendes N, Albergaria A, Farnie G, Gerhard R, Cameselle-Teijeiro JF, Seruca R, Schmitt F, Clarke RB, Paredes J.

Stem Cells. 2012 May;30(5):854-64. doi: 10.1002/stem.1075.

7.

Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.

Finkbeiner MR, Astanehe A, To K, Fotovati A, Davies AH, Zhao Y, Jiang H, Stratford AL, Shadeo A, Boccaccio C, Comoglio P, Mertens PR, Eirew P, Raouf A, Eaves CJ, Dunn SE.

Oncogene. 2009 Mar 19;28(11):1421-31. doi: 10.1038/onc.2008.485. Epub 2009 Jan 19.

PMID:
19151767
8.

Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.

Fujita T, Ito K, Izumi H, Kimura M, Sano M, Nakagomi H, Maeno K, Hama Y, Shingu K, Tsuchiya S, Kohno K, Fujimori M.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8837-44.

9.

Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.

Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, Marra M, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE.

Breast Cancer Res. 2007;9(5):R61.

10.

The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.

To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally M, Yapp D, Dunn SE.

Mol Pharmacol. 2007 Sep;72(3):641-52. Epub 2007 Jun 26. Erratum in: Mol Pharmacol. 2014 Mar;85(3):531-2.

11.

The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures.

Guay D, Evoy AA, Paquet E, Garand C, Bachvarova M, Bachvarov D, Lebel M.

Int J Biochem Cell Biol. 2008;40(11):2492-507. doi: 10.1016/j.biocel.2008.04.011. Epub 2008 May 15.

PMID:
18571458
12.

Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells.

Basaki Y, Hosoi F, Oda Y, Fotovati A, Maruyama Y, Oie S, Ono M, Izumi H, Kohno K, Sakai K, Shimoyama T, Nishio K, Kuwano M.

Oncogene. 2007 Apr 26;26(19):2736-46. Epub 2006 Oct 30.

PMID:
17072343
13.

Molecular decoy to the Y-box binding protein-1 suppresses the growth of breast and prostate cancer cells whilst sparing normal cell viability.

Law JH, Li Y, To K, Wang M, Astanehe A, Lambie K, Dhillon J, Jones SJ, Gleave ME, Eaves CJ, Dunn SE.

PLoS One. 2010 Sep 10;5(9). pii: e12661. doi: 10.1371/journal.pone.0012661.

14.
15.

Profiling of normal and malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used in combination with Ep-CAM/CD49f markers.

Ghebeh H, Sleiman GM, Manogaran PS, Al-Mazrou A, Barhoush E, Al-Mohanna FH, Tulbah A, Al-Faqeeh K, Adra CN.

BMC Cancer. 2013 Jun 14;13:289. doi: 10.1186/1471-2407-13-289.

16.

Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.

Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.

Clin Cancer Res. 2009 Jun 15;15(12):4234-41. doi: 10.1158/1078-0432.CCR-08-1479. Epub 2009 Jun 9.

17.

Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.

Toulany M, Schickfluss TA, Eicheler W, Kehlbach R, Schittek B, Rodemann HP.

Breast Cancer Res. 2011 Mar 10;13(2):R28. doi: 10.1186/bcr2845.

18.

YB-1 regulates Sox2 to coordinately sustain stemness and tumorigenic properties in a phenotypically distinct subset of breast cancer cells.

Jung K, Wu F, Wang P, Ye X, Abdulkarim BS, Lai R.

BMC Cancer. 2014 May 9;14:328. doi: 10.1186/1471-2407-14-328.

19.

Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy.

Fillmore CM, Kuperwasser C.

Breast Cancer Res. 2008;10(2):R25. doi: 10.1186/bcr1982. Epub 2008 Mar 26.

20.

Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression.

Bargou RC, Jürchott K, Wagener C, Bergmann S, Metzner S, Bommert K, Mapara MY, Winzer KJ, Dietel M, Dörken B, Royer HD.

Nat Med. 1997 Apr;3(4):447-50.

PMID:
9095180

Supplemental Content

Support Center